Protocol Ledger

NCT05208047 · Phase III · RECRUITING

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Interventional Phase III clinical trial protocol NCT05208047 sponsored by Cogent Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-14 Enrollment: 482 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05208047
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)482 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05208047
Protocol FieldVerified Registry Value
NCT IdentifierNCT05208047
Consolidated Lead SponsorCogent Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment482 participants (ESTIMATED)
Registered Start Date2022-04-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI